P3 Health Partners Reports $21 Million Q3 Adjusted EBITDA, Raises 2026 Guidance
P3 Health Partners reported Q3 2026 revenue of $396.3M, net income of $30.8M, and adjusted EBITDA of $20.9M. The company raised its 2026 adjusted EBITDA guidance midpoint to $100M. Membership decreased 9% YoY to 105,000, with total lives under management at 133,500. Management attributed improved medical cost trends to the positive results.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide a fresh catalyst for the stock, likely prompting buying interest.
Market read
First‑report earnings and guidance raise for a small‑cap health‑care company.
What to watch
Potential payer contract renegotiations could affect future margins.
Background
P3 Health Partners is a physician‑led health‑care network operating in five states.
Ticker impact
P3 Health Partners reported Q3 adjusted EBITDA of $20.9M and raised its full-year guidance midpoint to $100M.
likely upward pressure as investors price in higher EBITDA guidance
The company moved from a loss to positive EBITDA and lifted guidance, a clear catalyst for price appreciation.
Market effects
Healthcare services firms may see improved earnings expectations.
U.S. equity markets could react positively to the earnings beat.
Limited to investors focused on U.S. health‑care stocks.
Counterpoint
The guidance raise may already be priced in, limiting upside.
Key entities
- companyP3 Health Partners Inc.
U.S.-listed health‑care services provider (ticker PIII).
